• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两例迟发性皮肤卟啉病婴儿:口服S-腺苷-L-蛋氨酸和低剂量口服氯喹治疗成功

Two cases of infantile porphyria cutanea tarda: successful treatment with oral S-adenosyl-L-methionine and low-dose oral chloroquine.

作者信息

Battle A M, Stella A M, De Kaminsky A R, Kaminsky C, Mariano H G

出版信息

Br J Dermatol. 1987 Mar;116(3):407-15. doi: 10.1111/j.1365-2133.1987.tb05856.x.

DOI:10.1111/j.1365-2133.1987.tb05856.x
PMID:3567077
Abstract

In a 7-year-old girl and a 12-year-old boy, with photosensitivity and hypertrichosis, the diagnosis of familial porphyria cutanea tarda was confirmed by the characteristic pattern of urinary porphyrin excretion, diminished erythrocyte uroporphyrinogen decarboxylase and elevated plasma porphyrin index with emission maxima at 617-618 nm. The patients were treated with a combination of low-dose oral chloroquine and oral S-adenosyl-L-methionine (SAM); in one case alkalinization of urine was also applied. Complete clinical and biochemical recovery was achieved within 3 months. No adverse ophthalmological or other side-effects were observed. We propose that the treatment of choice should be oral SAM (12 mg/kg/day) for 3 weeks and oral chloroquine (2 X 100 mg weekly) for about 120-150 days or until improvement of clinical and biochemical abnormalities is attained. So far no relapses have occurred. This combined therapy appears to be safe, simple, effective and very convenient for both patients and physicians.

摘要

在一名7岁女孩和一名12岁男孩身上,出现了光敏性和多毛症,通过尿卟啉排泄的特征模式、红细胞尿卟啉原脱羧酶减少以及血浆卟啉指数升高(发射最大值在617 - 618纳米),确诊为家族性迟发性皮肤卟啉症。患者接受了低剂量口服氯喹和口服S - 腺苷 - L - 蛋氨酸(SAM)的联合治疗;在一个病例中还进行了尿液碱化处理。3个月内实现了完全的临床和生化恢复。未观察到不良眼科或其他副作用。我们建议,首选治疗方案应为口服SAM(12毫克/千克/天)3周,口服氯喹(每周2次,每次100毫克)约120 - 150天,或直至临床和生化异常得到改善。到目前为止尚未发生复发。这种联合治疗对患者和医生而言似乎都是安全、简单、有效且非常方便的。

相似文献

1
Two cases of infantile porphyria cutanea tarda: successful treatment with oral S-adenosyl-L-methionine and low-dose oral chloroquine.两例迟发性皮肤卟啉病婴儿:口服S-腺苷-L-蛋氨酸和低剂量口服氯喹治疗成功
Br J Dermatol. 1987 Mar;116(3):407-15. doi: 10.1111/j.1365-2133.1987.tb05856.x.
2
[Treatment of porphyria cutanea tarda with intermittent chloroquine].
Hautarzt. 1980 Aug;31(8):437-40.
3
Low-dose oral chloroquine in the treatment of porphyria cutanea tarda.
Br J Dermatol. 1984 Nov;111(5):609-13. doi: 10.1111/j.1365-2133.1984.tb06632.x.
4
Porphyria cutanea tarda and pregnancy.迟发性皮肤卟啉症与妊娠
Dermatologica. 1983 Jun;166(6):316-8. doi: 10.1159/000249898.
5
Correlation of serum and urinary porphyrin levels in porphyria cutanea tarda.迟发性皮肤卟啉病中血清和尿卟啉水平的相关性
Arch Dermatol. 1985 Oct;121(10):1289-91.
6
[Iron metabolism and chloroquine phosphate therapy in porphyria cutanea tarda].迟发性皮肤卟啉症中的铁代谢与磷酸氯喹治疗
Z Hautkr. 1990 Nov;65(11):1030-2, 1035.
7
[Results of treatment of porphyria cutanea tarda with bloodletting and chloroquine].[放血疗法与氯喹治疗迟发性皮肤卟啉症的结果]
Z Hautkr. 1990 Mar;65(3):223-5.
8
Treatment of porphyria cutanea tarda with chloroquine and phlebotomy.氯喹和放血疗法治疗迟发性皮肤卟啉症。
Br J Dermatol. 1977 Jul;97(1):77-81. doi: 10.1111/j.1365-2133.1977.tb15431.x.
9
Protective effect of S-adenosyl-L-methionine in hepatic uroporphyria. Evaluation in an experimental model.S-腺苷-L-蛋氨酸对肝性卟啉病的保护作用。在实验模型中的评估。
Scand J Gastroenterol. 1990 Oct;25(10):1034-40. doi: 10.3109/00365529008997631.
10
Porphyria Cutanea tarda in Missouri.密苏里州的迟发性皮肤卟啉症
Mo Med. 1981 Jun;78(6):299-302.

引用本文的文献

1
Hepatoerythropoietic porphyria precipitated by viral hepatitis.病毒性肝炎诱发的肝红细胞生成性卟啉病。
Gut. 1993 Nov;34(11):1632-4. doi: 10.1136/gut.34.11.1632.
2
S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism.S-腺苷-L-甲硫氨酸。综述其药理特性以及在肝功能障碍和情感障碍方面的治疗潜力,及其在细胞代谢中的生理作用。
Drugs. 1989 Sep;38(3):389-416. doi: 10.2165/00003495-198938030-00004.